Johnson & Johnson JNJ
NYSE JNJ
$270.24 +2.87 (+1.07%)
At close: Aug 21, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015)

Johnson & Johnson (JNJ) posted Current Deferred Tax Assets of $3.6 billion for Q3 2015, down 3.14% sequentially from $3.7 billion in Q2 2015, and down 5.77% YoY from $3.8 billion in Q3 2014.

Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015) Analysis & Trends

Johnson & Johnson has reported Current Deferred Tax Assets for 7 years, with the latest figure at $3.6 billion in Q3 2015.

  • Quarterly Current Deferred Tax Assets fell 5.77% year-over-year to $3.6 billion in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $3.6 billion (down 5.77% YoY) and the FY2014 annual result came in at $3.6 billion, down 1.11% from the prior year.
  • Current Deferred Tax Assets eased to $3.6 billion in Q3 2015 per JNJ's latest filing, from $3.7 billion in the prior quarter.
  • Over five years, Current Deferred Tax Assets peaked at $4.1 billion in Q2 2014 and troughed at $2.2 billion in Q1 2011.
  • A 5-year average of $3.2 billion and a median of $3.3 billion in 2012 frame the typical range for Current Deferred Tax Assets.
  • The sharpest annual moves came in 2011 and 2012: Current Deferred Tax Assets retreated 20.37% in 2011, then surged 35.17% in 2012.
  • Over 5 years, Current Deferred Tax Assets stood at $2.5 billion in 2011, then grew by 26.57% to $3.1 billion in 2012, then increased by 14.91% to $3.6 billion in 2013, then dropped by 1.11% to $3.6 billion in 2014, then increased by 1.09% to $3.6 billion in 2015.
  • According to Business Quant data, Current Deferred Tax Assets over the past three periods registered $3.6 billion, $3.7 billion, and $3.5 billion for Q3 2015, Q2 2015, and Q1 2015 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn

Historic Data

Download Data
DateValue
Sep 27, 2015 3.61 Bn
Sep 27, 2015 3.61 Bn
Jun 28, 2015 3.72 Bn
Jun 28, 2015 3.72 Bn
Mar 29, 2015 3.52 Bn
Mar 29, 2015 3.52 Bn
Dec 28, 2014 3.57 Bn
Dec 28, 2014 3.57 Bn
Sep 28, 2014 3.83 Bn
Sep 28, 2014 3.83 Bn
Jun 29, 2014 4.10 Bn
Jun 29, 2014 4.10 Bn
Mar 30, 2014 3.92 Bn
Mar 30, 2014 3.92 Bn
Dec 29, 2013 3.61 Bn
Dec 29, 2013 3.61 Bn
Sep 29, 2013 3.49 Bn
Sep 29, 2013 3.49 Bn
Jun 30, 2013 3.28 Bn
Jun 30, 2013 3.28 Bn